ALLO
Price
$1.57
Change
+$0.02 (+1.29%)
Updated
Apr 28 closing price
Capitalization
341.11M
One day until earnings call
GLYC
Price
$0.25
Change
-$0.01 (-3.85%)
Updated
Apr 29, 10:50 AM (EDT)
Capitalization
16.81M
2 days until earnings call
Ad is loading...

ALLO vs GLYC

Header iconALLO vs GLYC Comparison
Open Charts ALLO vs GLYCBanner chart's image
Allogene Therapeutics
Price$1.57
Change+$0.02 (+1.29%)
Volume$1.61M
Capitalization341.11M
GlycoMimetics
Price$0.25
Change-$0.01 (-3.85%)
Volume$125
Capitalization16.81M
ALLO vs GLYC Comparison Chart
Loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GLYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALLO vs. GLYC commentary
Apr 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a Hold and GLYC is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 29, 2025
Stock price -- (ALLO: $1.57 vs. GLYC: $0.26)
Brand notoriety: ALLO and GLYC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLO: 51% vs. GLYC: 41%
Market capitalization -- ALLO: $341.11M vs. GLYC: $16.81M
ALLO [@Biotechnology] is valued at $341.11M. GLYC’s [@Biotechnology] market capitalization is $16.81M. The market cap for tickers in the [@Biotechnology] industry ranges from $279.46B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLO’s FA Score shows that 0 FA rating(s) are green whileGLYC’s FA Score has 0 green FA rating(s).

  • ALLO’s FA Score: 0 green, 5 red.
  • GLYC’s FA Score: 0 green, 5 red.
According to our system of comparison, GLYC is a better buy in the long-term than ALLO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLO’s TA Score shows that 3 TA indicator(s) are bullish while GLYC’s TA Score has 5 bullish TA indicator(s).

  • ALLO’s TA Score: 3 bullish, 4 bearish.
  • GLYC’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, GLYC is a better buy in the short-term than ALLO.

Price Growth

ALLO (@Biotechnology) experienced а +10.56% price change this week, while GLYC (@Biotechnology) price change was +18.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.44%. For the same industry, the average monthly price growth was -1.76%, and the average quarterly price growth was -11.06%.

Reported Earning Dates

ALLO is expected to report earnings on Aug 06, 2025.

GLYC is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+4.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALLO($341M) has a higher market cap than GLYC($16.8M). GLYC YTD gains are higher at: 4.618 vs. ALLO (-26.291). GLYC has higher annual earnings (EBITDA): -32.47M vs. ALLO (-243.33M). ALLO has more cash in the bank: 292M vs. GLYC (10.7M). GLYC has less debt than ALLO: GLYC (66.8K) vs ALLO (90.8M). ALLO has higher revenues than GLYC: ALLO (22K) vs GLYC (0).
ALLOGLYCALLO / GLYC
Capitalization341M16.8M2,030%
EBITDA-243.33M-32.47M749%
Gain YTD-26.2914.618-569%
P/E RatioN/AN/A-
Revenue22K0-
Total Cash292M10.7M2,729%
Total Debt90.8M66.8K135,928%
FUNDAMENTALS RATINGS
ALLO vs GLYC: Fundamental Ratings
ALLO
GLYC
OUTLOOK RATING
1..100
933
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
88
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
8252
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GLYC's Valuation (88) in the Biotechnology industry is in the same range as ALLO (97). This means that GLYC’s stock grew similarly to ALLO’s over the last 12 months.

GLYC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ALLO (100). This means that GLYC’s stock grew similarly to ALLO’s over the last 12 months.

ALLO's SMR Rating (97) in the Biotechnology industry is in the same range as GLYC (99). This means that ALLO’s stock grew similarly to GLYC’s over the last 12 months.

GLYC's Price Growth Rating (52) in the Biotechnology industry is in the same range as ALLO (82). This means that GLYC’s stock grew similarly to ALLO’s over the last 12 months.

GLYC's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ALLO (100). This means that GLYC’s stock grew similarly to ALLO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLOGLYC
RSI
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
85%
MACD
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
N/A
Bullish Trend 5 days ago
81%
Declines
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 23 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
88%
Aroon
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GLYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X94978.7500001223.914100
+1.31%
Bitcoin cryptocurrency
GME27.590.13
+0.47%
GameStop Corp
AAPL210.140.86
+0.41%
Apple
TSLA285.880.93
+0.33%
Tesla
SPY550.850.21
+0.04%
SPDR® S&P 500® ETF

ALLO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with CRSP. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLO
1D Price
Change %
ALLO100%
+1.29%
CRSP - ALLO
59%
Loosely correlated
-1.02%
FATE - ALLO
55%
Loosely correlated
-2.34%
NTLA - ALLO
55%
Loosely correlated
+2.05%
CRBU - ALLO
50%
Loosely correlated
-0.30%
PRME - ALLO
50%
Loosely correlated
-1.78%
More

GLYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLYC has been closely correlated with LYRA. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if GLYC jumps, then LYRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLYC
1D Price
Change %
GLYC100%
-0.19%
LYRA - GLYC
76%
Closely correlated
-5.24%
ROQAF - GLYC
72%
Closely correlated
N/A
EYPT - GLYC
47%
Loosely correlated
+6.44%
IONS - GLYC
35%
Loosely correlated
+0.13%
ALLO - GLYC
33%
Loosely correlated
+1.29%
More